Document is current

Article History

Received: 17 July 2020

Accepted: 3 March 2021

First Online: 16 March 2021

Declarations

:

: The study was reviewed by the research ethics board at the Centre for Addiction and Mental Health (approval number: 035-2015). Informed consent from health care providers’ to participate in the study was obtained via written consent before the interview was conducted.

: Not applicable.

: The authors declare that they have no competing interest with regards to this manuscript. However, some authors have general disclosures to report. PS reports receiving grants and/or salary and/or research support from Centre for Addiction and Mental Health, Health Canada, Ontario Ministry of Health and Long-Term care, Canadian Institutes of Health Research (CIHR), Canadian Centre on Substance Use and Addiction, Public Health Agency of Canada, Medical Psychiatry Alliance, Canadian Cancer Society Research Institute, Cancer Care Ontario, and the Ontario Institute for Cancer Research, McLaughlin Centre, Academic Health Sciences Centre, Workplace Safety and Insurance Board, National Institutes of Health, The Association of Faculties of Medicine of Canada. PS also reports receiving funding from the following commercial organizations: Pfizer Inc./Pfizer Canada, Bhasin Consulting Fund, Shoppers Drug Mart and Patient-Centered Outcomes Research Institute, ABBVie, Bristol-Myers Squibb; and has received consulting fees from Pfizer Inc./Pfizer Canada, Johnson & Johnson Group of Companies, MedPlan Communications, Evidera Inc., Kataka Medical Communications, Miller Medical Communications, Nvision, Insight Group, Sun Life Financial, Inflexxion Inc. Through an open tender process, Johnson & Johnson, Novartis, and Pfizer Inc. are vendors of record for providing smoking cessation pharmacotherapy, free or discounted, for research studies in which PS is the principal investigator or co-investigator. BL has obtained funding from Pfizer (GRAND Awards, including salary support) for investigator-initiated projects. BL has/will receive some in-kind donation of cannabis product from Canopy and Aurora and medication donation from Pfizer and Bioprojet and was provided a coil for TMS study from Brainsway. BL has/will perform research with industry funding obtained from Canopy (through research grants handled by CAMH or University of Toronto, Aphria (through research grants handled by CAMH or University of Toronto), Bioprojet, ACS and Alkermes. BL has received in kind donations of nabiximols from GW Pharma for past studies funded by CIHR and NIH.